{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T18:04:01Z","timestamp":1779041041831,"version":"3.51.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"Supplement_C","license":[{"start":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T00:00:00Z","timestamp":1588118400000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Introduction<\/jats:title>\n               <jats:p>The majority of patients with severe aortic stenosis are recommended intervention with a surgical biological prosthesis (bioSAVR) or a transcatheter aortic valve intervention (TAVI). The antithrombotic strategies after aortic valve intervention vary and include drugs targeting both platelets and the coagulation cascade. Long-term exposure and changes of antithrombotic treatment influence the risk of both bleeding and thromboembolic events.The aim was to describe an unselected sample of patients who have experienced haemorrhagic stroke and other major bleeding events after biological aortic prosthesis, their antithrombotic treatment and changes of treatments in relation to the bleeding event.All patients performing an bioSAVR or a TAVI 2008\u20132014 were identified in the SWEDEHEART registry and included in the study (n\u2009=\u200910\u2009711). The outcome events were haemorrhagic stroke and other major bleeding event. Information of drug exposure was collected from the dispensed drug registry.The incidence rate of any bleeding event was 2.85\/100 patient-years the first year after aortic valve intervention. Heart failure and atrial fibrillation were present more often in patients with a first haemorrhagic stroke or other major bleeding event compared to without. The proportion of exposure to warfarin was 28.7% vs. 21.3% in patients with and without a haemorrhagic stroke. Comparable figures were 31.2% vs. 19.0% in patients with and without other major bleeding event. During 1 month prior a haemorrhagic stroke or other major bleeding event 39.4% and 38.0%, respectively, of the patients not previously exposed to antithrombotic treatment started warfarin or single antiplatelet therapy.Major bleeding events are not uncommon after aortic valve intervention with a biological prosthesis. Evaluation of comorbidities and previous bleeding might improve risk stratification for bleeding in these elderly patients. The pattern of change of antithrombotic treatment was similar in the groups with and without a bleeding event and in most patients the antithrombotic regime was unchanged the month before an event.<\/jats:p>","DOI":"10.1093\/eurheartj\/suaa007","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:56:00Z","timestamp":1588161360000},"page":"C26-C33","source":"Crossref","is-referenced-by-count":4,"title":["Haemorrhagic stroke and major bleeding after intervention with biological aortic valve prosthesis: risk factors and antithrombotic treatment"],"prefix":"10.1093","volume":"22","author":[{"given":"Christina","family":"Christersson","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, SE 75185 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"St\u00e5hle","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, Thoracic surgery, Uppsala University, SE 75185 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Lindhagen","sequence":"first","affiliation":[{"name":"Uppsala Clinical Research Center, Uppsala University, SE 75185 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"James","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, SE 75185 Uppsala, Sweden"},{"name":"Uppsala Clinical Research Center, Uppsala University, SE 75185 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,29]]},"reference":[{"key":"2020042907555327300_suaa007-B1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjcard.2018.04.006","article-title":"Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation","volume":"122","author":"Maes","year":"2018","journal-title":"Am J Cardiol"},{"key":"2020042907555327300_suaa007-B2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2020042907555327300_suaa007-B3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10557-019-06911-y","article-title":"Bleeding risk scores and scales of frailty for the prediction of haemorrhagic events in older adults with acute coronary syndrome: insights from the FRASER study","volume":"33","author":"Pavasini","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020042907555327300_suaa007-B4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.amjcard.2019.07.003","article-title":"Relation of frailty to outcomes in patients with acute coronary syndromes","volume":"124","author":"Kwok","year":"2019","journal-title":"Am J Cardiol"},{"key":"2020042907555327300_suaa007-B5","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2020042907555327300_suaa007-B6","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"key":"2020042907555327300_suaa007-B7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/heartjnl-2018-314313","article-title":"Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation","volume":"105","author":"Nijenhuis","year":"2019","journal-title":"Heart"},{"key":"2020042907555327300_suaa007-B8","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1001\/jama.2012.54506","article-title":"Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding","volume":"308","author":"Merie","year":"2012","journal-title":"JAMA"},{"key":"2020042907555327300_suaa007-B9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.ajkd.2016.10.018","article-title":"Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation","volume":"69","author":"Jun","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2020042907555327300_suaa007-B10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/1076029612470967","article-title":"Antithrombotic medication use and bleeding risk in medically ill patients after hospitalization","volume":"19","author":"Mahan","year":"2013","journal-title":"Clin Appl Thromb Hemost"},{"key":"2020042907555327300_suaa007-B11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"},{"key":"2020042907555327300_suaa007-B12","doi-asserted-by":"crossref","first-page":"450.","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2020042907555327300_suaa007-B13","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.07.040","article-title":"Antithrombotic treatment prior to intracerebral hemorrhage: analysis in the National Acute Stroke Israeli Registry","volume":"27","author":"Romem","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2020042907555327300_suaa007-B14","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2020042907555327300_suaa007-B15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1161\/CIRCRESAHA.116.304723","article-title":"The epidemiology of blood pressure and its worldwide management","volume":"116","author":"Rahimi","year":"2015","journal-title":"Circ Res"},{"key":"2020042907555327300_suaa007-B16","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.1538-7836.2011.04437.x","article-title":"Differential propensity for major hemorrhagic events in patients with different types of arterial disease","volume":"9","author":"Achterberg","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2020042907555327300_suaa007-B17","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/STROKEAHA.108.540781","article-title":"Sex differences in stroke epidemiology: a systematic review","volume":"40","author":"Appelros","year":"2009","journal-title":"Stroke"},{"key":"2020042907555327300_suaa007-B18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/03009734.2017.1407849","article-title":"The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients","volume":"122","author":"Christersson","year":"2017","journal-title":"Ups J Med Sci"},{"key":"2020042907555327300_suaa007-B19","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1160\/TH15-05-0395","article-title":"History of previous bleeding and C-reactive protein improve assessment of bleeding risk in elderly patients (\u226580 years) with myocardial infarction","volume":"114","author":"Koller","year":"2015","journal-title":"Thromb Haemost"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_C\/C26\/33144422\/suaa007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_C\/C26\/33144422\/suaa007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:56:34Z","timestamp":1588161394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/22\/Supplement_C\/C26\/5826772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":19,"journal-issue":{"issue":"Supplement_C","published-online":{"date-parts":[[2020,4,29]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suaa007","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,4,1]]}}}